{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:10:01Z","timestamp":1790428201904,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1007\/s11914-996-0011-8","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T18:44:30Z","timestamp":1180118670000},"page":"123-130","source":"Crossref","is-referenced-by-count":15,"title":["Combination\/sequential therapy in osteoporosis"],"prefix":"10.1007","volume":"2","author":[{"given":"Marie-Paul","family":"Lecart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bruyere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","volume":"359","author":"PD Delmas","year":"2002","unstructured":"Delmas PD: Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018\u20132026.","journal-title":"Lancet"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-117-1-1","volume":"117","author":"EG Lufkin","year":"1992","unstructured":"Lufkin EG, Wahner HW, O\u2019Fallon WM, et al.: Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992, 117:1\u20139.","journal-title":"Ann Intern Med"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","volume":"109","author":"C Chesnut III","year":"2000","unstructured":"Chesnut C III, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000, 109:267\u2013276.","journal-title":"Am J Med"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999, 282:637\u2013645.","journal-title":"JAMA"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al.: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535\u20131541.","journal-title":"Lancet"},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s001980050041","volume":"8","author":"PJ Meunier","year":"1998","unstructured":"Meunier PJ, Sebert JL, Reginster J-Y, et al.: Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVO Study Group. Osteoporos Int 1998, 8:4\u201312.","journal-title":"Osteoporos Int"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-129-1-199807010-00001","volume":"129","author":"JY Reginster","year":"1998","unstructured":"Reginster JY, Meurmans L, Zegels B, et al.: The effect of sodium monofluorophosphatase plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 1998, 129:1\u20138.","journal-title":"Ann Intern Med"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434\u20131441. The first methodologically sound study unequivocally demonstrating the antifracture efficacy of an anabolic agent in the management of osteoporosis.","journal-title":"N Engl J Med"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s001980200026","volume":"13","author":"MR Rubin","year":"2002","unstructured":"Rubin MR, Cosman F, Lindsay R, Bilezikian JP: The anabolic effects of parathyroid hormone. Osteoporos Int 2002, 13:267\u2013277.","journal-title":"Osteoporos Int"},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E, et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459\u2013468. The demonstration that a compound able to concomitantly reduce bone resorption and stimulate bone formation is able to reduce vertebral fracture rates in postmenopausal osteoporosis.","journal-title":"N Engl J Med"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J-Y Reginster","year":"2000","unstructured":"Reginster J-Y, Minne HW, Sorensen OH, et al.: Randomized trial of the effect of risedronate on vertebral fractures in momen with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83\u201391.","journal-title":"Osteoporos Int"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","volume":"16","author":"BJ Riis","year":"2001","unstructured":"Riis BJ, Ise J, Von Stein T, et al.: Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001, 16:1871\u20131878.","journal-title":"J Bone Miner Res"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","volume":"322","author":"T Storm","year":"1990","unstructured":"Storm T, Thamsborg G, Steiniche T, et al.: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990, 322:1265\u20131271.","journal-title":"N Engl J Med"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0149-2918(00)87972-2","volume":"22","author":"HG Bone","year":"2000","unstructured":"Bone HG, Adami S, Rizzoli R, et al.: Weekly administration of alendronate: rationale and plan for clinical assessement. Clin Ther 2000, 22:1\u201314.","journal-title":"Clin Ther"},{"key":"11_CR15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","volume":"34","author":"S Adami","year":"2004","unstructured":"Adami S, Felsenberg D, Christiansen C, et al.: Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004, 34:881\u2013889.","journal-title":"Bone"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653\u2013661.","journal-title":"N Engl J Med"},{"key":"11_CR17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00198-004-1621-6","volume":"15","author":"S Boonen","year":"2004","unstructured":"Boonen S, Rizzoli R, Meunier PJ, et al.: The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 2004, 15:511\u2013519.","journal-title":"Osteoporos Int"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","volume":"15","author":"T Mashiba","year":"2000","unstructured":"Mashiba T, Hirano T, Turner CH, et al.: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613\u2013620.","journal-title":"J Bone Miner Res"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1385\/JCD:3:2:187","volume":"3","author":"SJ Wimalawansa","year":"2000","unstructured":"Wimalawansa SJ: Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents. J Clin Densitom 2000, 3:187\u2013201.","journal-title":"J Clin Densitom"},{"key":"11_CR20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA 2002, 288:321\u2013333.","journal-title":"JAMA"},{"key":"11_CR21","first-page":"3076","volume":"84","author":"R Lindsay","year":"1999","unstructured":"Lindsay R, Cosman F, Lobo RA, et al.: Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999, 84:3076\u20133081.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.289.19.2525","volume":"289","author":"SL Greenspan","year":"2003","unstructured":"Greenspan SL, Resnick NM, Parker RA: Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women. A randomized controlled trial. JAMA 2003, 289:2525\u20132532.","journal-title":"JAMA"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","volume":"137","author":"SL Greenspan","year":"2002","unstructured":"Greenspan SL, Emkey RD, Bone HG III, et al.: Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002, 137:875\u2013883.","journal-title":"Ann Intern Med"},{"key":"11_CR24","first-page":"720","volume":"85","author":"HG Bone","year":"2000","unstructured":"Bone HG, Greenspan SL, McKeever C, et al.: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000, 85:720\u2013726.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR25","first-page":"536","volume":"80","author":"I Davas","year":"2003","unstructured":"Davas I, Altintas A, Yoldemir T, et al.: Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women. Menopause 2003, 80:536\u2013540.","journal-title":"Menopause"},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/humrep\/15.10.2087","volume":"15","author":"MB Tiras","year":"2000","unstructured":"Tiras MB, Noyan V, Yildirim M, Daya D: Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Hum Reprod 2000, 15:2087\u20132092.","journal-title":"Hum Reprod"},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/jcem.87.4.8323","volume":"87","author":"S Palomba","year":"2002","unstructured":"Palomba S, Orio F, Colao A, et al.: Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:1502\u20131508.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9343(99)80102-8","volume":"99","author":"SJ Wimalawansa","year":"1995","unstructured":"Wimalawansa SJ: Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995, 99:36\u201342.","journal-title":"Am J Med"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9343(98)00029-1","volume":"104","author":"SJ Wimalawansa","year":"1998","unstructured":"Wimalawansa SJ: A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998, 104:219\u2013226.","journal-title":"Am J Med"},{"key":"11_CR30","first-page":"1890","volume":"86","author":"ST Harris","year":"2001","unstructured":"Harris ST, Eriksen EF, Davidson M, et al.: Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001, 86:1890\u20131897.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR31","first-page":"239","volume-title":"Recent Research on Gynecological Endocrinology","author":"SJ Wimalawansa","year":"1998","unstructured":"Wimalawansa SJ, Stevenson JC, Banks LM, et al.: Prevention of postmenopausal bone loss with small doses of calcitonin and percutaneous oestrogen. In Recent Research on Gynecological Endocrinology. Edited by Genazzani AR, Petraglia F, Volpe A, Facchinetti F. London: Parthenon Publishers; 1998:239\u2013244."},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF01352009","volume":"53","author":"M Meschia","year":"1993","unstructured":"Meschia M, Brincat M, Barbacini P, et al.: A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993, 53:17\u201320.","journal-title":"Calcif Tissue Int"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/09513599709152548","volume":"11","author":"D Aloysio de","year":"1997","unstructured":"de Aloysio D, Gambacciani M, Altieri P, et al.: Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT. Gynecol Endocrinol 1997, 11:289\u2013293.","journal-title":"Gynecol Endocrinol"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","volume":"87","author":"O Johnell","year":"2002","unstructured":"Johnell O, Scheele WH, Lu Y, et al.: Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodelling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:985\u2013992.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR35","first-page":"227","volume":"143","author":"HM Frost","year":"1979","unstructured":"Frost HM: Treatment of osteoporosis by manipulation of coherent bone cell populations. Clin Orthop 1979, 143:227\u2013244.","journal-title":"Clin Orthop"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","volume":"350","author":"R Lindsay","year":"1997","unstructured":"Lindsay R, Nieves J, Formica C, et al.: Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550\u2013555.","journal-title":"Lancet"},{"key":"11_CR37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","volume":"16","author":"F Cosman","year":"2001","unstructured":"Cosman F, Nieves J, Woelfert L, et al.: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925\u2013931.","journal-title":"J Bone Miner Res"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 1998, 102:1627\u20131633. An interesting study performed in patients with corticosteroidinduced osteoporosis showing that PTH treatment may be initiated in patients receiving chronic HT.","journal-title":"J Clin Invest"},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","volume":"15","author":"NE Lane","year":"2000","unstructured":"Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944\u2013951.","journal-title":"J Bone Miner Res"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G, Pavo I: Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745\u2013750. The demonstration that PTH treatment may be initiated in patients previously treated with raloxifene or alendronate.","journal-title":"J Bone Miner Res"},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF02556561","volume":"44","author":"R-D Hesch","year":"1989","unstructured":"Hesch R-D, Busch U, Prokop M, et al.: Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 1989, 44:176\u2013180.","journal-title":"Calcif Tissue Int"},{"key":"11_CR42","first-page":"620","volume":"82","author":"AB Hodsman","year":"1997","unstructured":"Hodsman AB, Fraher LJ, Watson PH, et al.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997, 82:620\u2013628.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF01625448","volume":"1","author":"J Reeve","year":"1991","unstructured":"Reeve J, Bradbeer JN, Arlot M, et al.: hPTh 1\u201334 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int 1991, 1:162\u2013170.","journal-title":"Osteoporos Int"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.1992.tb02323.x","volume":"37","author":"JN Bradbeer","year":"1992","unstructured":"Bradbeer JN, Arlot ME, Meunier PJ, Reeve J: Treatment of osteoporosis with parathyroid peptide (hPTH 1\u201334) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol 1992, 37:282\u2013289.","journal-title":"Clin Endocrinol"},{"key":"11_CR45","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1210\/endo.134.5.8156913","volume":"134","author":"L Mosekilde","year":"1994","unstructured":"Mosekilde L, Danielson CC, Gasser J: The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone (1-38), and combination therapy, assess in aged ovariectomized rats. Endocrinology 1994, 134:2126\u20132134.","journal-title":"Endocrinology"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/8756-3282(95)00115-T","volume":"16","author":"M Li","year":"1995","unstructured":"Li M, Mosekilde L, Sogaard CH, et al.: Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 1995, 16:629\u2013635.","journal-title":"Bone"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/jbmr.5650040321","volume":"4","author":"JM Hock","year":"1989","unstructured":"Hock JM, Hummert JR, Boyce R, et al.: Resorption is not essential for the stimulation of bone growth by hPTH(1-34) in rats in vivo. J Bone Miner Res 1989, 4:449\u2013458.","journal-title":"J Bone Miner Res"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/8756-3282(94)90816-8","volume":"15","author":"L Mosekilde","year":"1994","unstructured":"Mosekilde L, Sogaard CH, McOsker JE, Wronski TJ: PTH has more pronounced effect on vertebral bone mass and biochemical competence than antiresorptive agents (estrogen and bisphosphonate) assessed in sexually mature, ovariectomized rats. Bone 1994, 15:401\u2013408.","journal-title":"Bone"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/8756-3282(95)00113-R","volume":"16","author":"PD Delmas","year":"1995","unstructured":"Delmas PD, Vergnaud P, Arlot ME, et al.: The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption in inhibited by the bisphosphonate tiludronate. Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodelling system? Bone 1995, 16:603\u2013610.","journal-title":"Bone"},{"key":"11_CR50","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1359\/jbmr.1997.12.3.343","volume":"12","author":"L Mosekilde","year":"1997","unstructured":"Mosekilde L, Thomsen JS, Kneissel M, Gasser JA: Alendronate blunts the anabolic effect of a PTH analog, SDZ PTS 893, when administered sequentially. J Bone Miner Res 1997, 12:S343.","journal-title":"J Bone Miner Res"},{"key":"11_CR51","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.1998.13.6.1051","volume":"13","author":"F Cosman","year":"1998","unstructured":"Cosman F, Nieves J, Woelfert L, et al.: Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998, 13:1051\u20131055.","journal-title":"J Bone Miner Res"},{"key":"11_CR52","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207\u20131215. This study reports the absence of synergistic effect of alendronate and PTH and concludes that this association should not be recommended in the management of osteoporosis.","journal-title":"N Engl J Med"},{"key":"11_CR53","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216\u20131226.","journal-title":"N Engl J Med"},{"key":"11_CR54","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMe038143","volume":"349","author":"S Khosla","year":"2003","unstructured":"Khosla S: Parathyroid hormone plus alendronate - A combination that does not add up. N Engl J Med 2003, 349:1277\u20131279.","journal-title":"N Engl J Med"},{"key":"11_CR55","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s00198-003-1397-0","volume":"14","author":"N Morabito","year":"2003","unstructured":"Morabito N, Gaudio A, Lasco A, et al.: Three-year effectiveness of intravenous pamidronate versus pamidronate plus slowrelease sodium fluoride for postmenopausal osteoporosis. Osteoporos Int 2003, 14:500\u2013506.","journal-title":"Osteoporos Int"},{"key":"11_CR56","first-page":"3013","volume":"84","author":"P Alexandersen","year":"1999","unstructured":"Alexandersen P, Riis BJ, Christiansen C: Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab 1999, 84:3013\u20133020.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s001980200008","volume":"13","author":"DH Gutteridge","year":"2002","unstructured":"Gutteridge DH, Stewart GO, Prince RL, et al.: A randomized trial of sodium fluoride (60 mg) + estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures. Osteoporos Int 2002, 13:158\u2013170.","journal-title":"Osteoporos Int"},{"key":"11_CR58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/09513599909167580","volume":"13","author":"J-Y Reginster","year":"1999","unstructured":"Reginster J-Y, Agnusdei D, Gennari C, Kicovic PM: Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women. Gynecol Endocrinol 1999, 13:361\u2013368.","journal-title":"Gynecol Endocrinol"},{"key":"11_CR59","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00198-003-1432-1","volume":"14","author":"J-Y Reginster","year":"2003","unstructured":"Reginster J-Y, Felsenberg D, Pavo I, et al.: Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int 2003, 14:741\u2013749.","journal-title":"Osteoporos Int"},{"key":"11_CR60","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2265.1995.tb02920.x","volume":"43","author":"RJ Erdtsieck","year":"1995","unstructured":"Erdtsieck RJ, Pols HAP, Valk NK, et al.: Treatment of postmenopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. Clin Endocrinol 1995, 43:557\u2013565.","journal-title":"Clin Endocrinol"},{"key":"11_CR61","first-page":"1111","volume":"82","author":"L Holloway","year":"1997","unstructured":"Holloway L, Kohlmeier L, Kent K, Marcus R: Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab 1997, 82:1111\u20131117.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR62","first-page":"1116","volume":"86","author":"MG Murphy","year":"2001","unstructured":"Murphy MG, Weiss S, McClung M, et al.: Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001, 86:1116\u20131125.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR63","first-page":"2129","volume":"85","author":"RS Rittmaster","year":"2000","unstructured":"Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Met 2000, 85:2129\u20132134.","journal-title":"J Clin Endocrinol Met"},{"key":"11_CR64","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1359\/JBMR.040123","volume":"19","author":"Y Rhee","year":"2004","unstructured":"Rhee Y, Won Y-Y, Baek M-H, Lim S-K: Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats. J Bone Miner Res 2004, 19:931\u2013937.","journal-title":"J Bone Miner Res"},{"key":"11_CR65","first-page":"141","volume":"3","author":"N Maalouf","year":"2003","unstructured":"Maalouf N, Wehbe J, Nehme A, et al.: Osteoporosis: combination therapy for better or worse. J Musculo Neuron Interact 2003, 3:141\u2013147.","journal-title":"J Musculo Neuron Interact"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-996-0011-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-996-0011-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-996-0011-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:33:58Z","timestamp":1559421238000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-996-0011-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11914-996-0011-8","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}